サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411553

細胞・遺伝子治療の生物学的製剤CDMO市場：構成要素、フェーズ、適応症別-2024-2030年の世界予測

Cell & Gene Therapy Biomanufacturing CDMO Market by Component (Cell Therapy, Plasmid DNA, Viral Vector), Phase (Phase 1, Phase 2, Phase 3), Indication - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
細胞・遺伝子治療の生物学的製剤CDMO市場：構成要素、フェーズ、適応症別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞・遺伝子治療の生物学的製剤CDMO市場規模は、2023年に3億3,812万米ドルと推定され、2024年には4億8,547万米ドルに達し、CAGR 32.53%で2030年には24億2,890万米ドルに達すると予測されます。

細胞・遺伝子治療の生物学的製剤CDMOの世界市場

主な市場の統計
基準年[2023］ 3億3,812万米ドル
予測年 [2024] 4億8,547万米ドル
予測年 [2030] 24億2,890万米ドル
CAGR（%） 32.53%
Cell &Gene Therapy Biomanufacturing CDMO Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは細胞・遺伝子治療の生物学的製剤CDMO市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、細胞・遺伝子治療の生物学的製剤CDMO市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-細胞・遺伝子治療の生物学的製剤CDMO市場の市場規模および予測は？

2-細胞・遺伝子治療の生物学的製剤CDMO市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-細胞・遺伝子治療の生物学的製剤CDMO市場における技術動向と規制の枠組みは？

4-細胞・遺伝子治療の生物学的製剤CDMO市場における主要ベンダーの市場シェアは？

5-細胞・遺伝子治療の生物学的製剤CDMO市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 細胞工学、遺伝子工学および治療における研究開発活動の増加
      • 慢性疾患や遺伝性疾患を治すための遺伝子治療の必要性が高まっている
      • CDMOと大手企業との間の協力活動の増加
    • 抑制要因
      • CDMOサービスのコストが高い
    • 機会
      • デジタル化やAI技術を取り込むCDMOの取り組み
      • バイオテクノロジーと製薬のスタートアップの数が増加
    • 課題
      • 遺伝子調査を取り巻く複雑な規制
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 細胞・遺伝子治療の生物学的製剤CDMO市場：コンポーネント別

  • 細胞治療
  • プラスミドDNA
  • ウイルスベクター

第7章 細胞・遺伝子治療の生物学的製剤CDMO市場フェーズ別

  • フェーズ 1
  • フェーズ2
  • フェーズ 3
  • フェーズ4

第8章 細胞・遺伝子治療の生物学的製剤CDMO市場適応症別

  • がん
  • 循環器疾患
  • 遺伝性疾患
  • 感染症
  • 神経学的障害

第9章 南北アメリカの細胞・遺伝子治療の生物学的製剤CDMO市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の細胞・遺伝子治療の生物学的製剤CDMO市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの細胞・遺伝子治療の生物学的製剤CDMO市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AGC Biologics
    • Almac Group
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • Catalent Inc.,
    • Charles River Laboratories International Inc.
    • Danaher Corporation
    • Endress+Hauser Group Services AG
    • FUJIFILM Diosynth Biotechnologies
    • GC Corporation
    • General Electric Company
    • Getinge AB
    • Infors AG
    • Lonza Group Ltd
    • Merck KGaA
    • Miltenyi Biotec B.V. & Co. KG
    • Patheon Inc.
    • PCI Pharma Services
    • Pfizer CentreOne
    • PIERRE GUERIN
    • Recipharm AB
    • Samsung Biologics
    • Sartorius AG
    • Thermo Fisher Scientific
    • uBriGene
    • WuXi Advanced Therapies
    • WuXi AppTec
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET DYNAMICS
  • FIGURE 7. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 8. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 10. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 10. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 3, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 148. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET LICENSE & PRICING
目次
Product Code: MRR-5C6F41F5AFAD

[193 Pages Report] The Cell & Gene Therapy Biomanufacturing CDMO Market size was estimated at USD 338.12 million in 2023 and expected to reach USD 485.47 million in 2024, at a CAGR 32.53% to reach USD 2,428.90 million by 2030.

Global Cell & Gene Therapy Biomanufacturing CDMO Market

KEY MARKET STATISTICS
Base Year [2023] USD 338.12 million
Estimated Year [2024] USD 485.47 million
Forecast Year [2030] USD 2,428.90 million
CAGR (%) 32.53%
Cell & Gene Therapy Biomanufacturing CDMO Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cell & Gene Therapy Biomanufacturing CDMO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cell & Gene Therapy Biomanufacturing CDMO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Biomanufacturing CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics, Almac Group, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Catalent Inc.,, Charles River Laboratories International Inc., Danaher Corporation, Endress+Hauser Group Services AG, FUJIFILM Diosynth Biotechnologies, GC Corporation, General Electric Company, Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Patheon Inc., PCI Pharma Services, Pfizer CentreOne, PIERRE GUERIN, Recipharm AB, Samsung Biologics, Sartorius AG, Thermo Fisher Scientific, uBriGene, WuXi Advanced Therapies, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Biomanufacturing CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • Cell Therapy
    • Plasmid DNA
    • Viral Vector
  • Phase
    • Phase 1
    • Phase 2
    • Phase 3
    • Phase 4
  • Indication
    • Cancer
    • Cardiovascular Disease
    • Genetic Disorders
    • Infectious Disease
    • Neurological Disorders
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cell & Gene Therapy Biomanufacturing CDMO Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cell & Gene Therapy Biomanufacturing CDMO Market?

3. What are the technology trends and regulatory frameworks in the Cell & Gene Therapy Biomanufacturing CDMO Market?

4. What is the market share of the leading vendors in the Cell & Gene Therapy Biomanufacturing CDMO Market?

5. Which modes and strategic moves are suitable for entering the Cell & Gene Therapy Biomanufacturing CDMO Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cell & Gene Therapy Biomanufacturing CDMO Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of R&D activities in cellular and genetic engineering and therapies
      • 5.1.1.2. Increasing need for genetic treatments to cure chronic and genetic disorders
      • 5.1.1.3. Rising number of collaborative activities between CDMOs and major players
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of CDMO services
    • 5.1.3. Opportunities
      • 5.1.3.1. Efforts by CDMOs to incorporate digitalization and AI technologies
      • 5.1.3.2. Rising number of biotechnology and pharmaceutical startups
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulations surrounding genetic and cell research
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Cell & Gene Therapy Biomanufacturing CDMO Market, by Component

  • 6.1. Introduction
  • 6.2. Cell Therapy
  • 6.3. Plasmid DNA
  • 6.4. Viral Vector

7. Cell & Gene Therapy Biomanufacturing CDMO Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase 1
  • 7.3. Phase 2
  • 7.4. Phase 3
  • 7.5. Phase 4

8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Indication

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Disease
  • 8.4. Genetic Disorders
  • 8.5. Infectious Disease
  • 8.6. Neurological Disorders

9. Americas Cell & Gene Therapy Biomanufacturing CDMO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cell & Gene Therapy Biomanufacturing CDMO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cell & Gene Therapy Biomanufacturing CDMO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AGC Biologics
    • 13.1.2. Almac Group
    • 13.1.3. Becton, Dickinson and Company
    • 13.1.4. Bio-Rad Laboratories, Inc.
    • 13.1.5. Bio-Techne Corporation
    • 13.1.6. Catalent Inc.,
    • 13.1.7. Charles River Laboratories International Inc.
    • 13.1.8. Danaher Corporation
    • 13.1.9. Endress+Hauser Group Services AG
    • 13.1.10. FUJIFILM Diosynth Biotechnologies
    • 13.1.11. GC Corporation
    • 13.1.12. General Electric Company
    • 13.1.13. Getinge AB
    • 13.1.14. Infors AG
    • 13.1.15. Lonza Group Ltd
    • 13.1.16. Merck KGaA
    • 13.1.17. Miltenyi Biotec B.V. & Co. KG
    • 13.1.18. Patheon Inc.
    • 13.1.19. PCI Pharma Services
    • 13.1.20. Pfizer CentreOne
    • 13.1.21. PIERRE GUERIN
    • 13.1.22. Recipharm AB
    • 13.1.23. Samsung Biologics
    • 13.1.24. Sartorius AG
    • 13.1.25. Thermo Fisher Scientific
    • 13.1.26. uBriGene
    • 13.1.27. WuXi Advanced Therapies
    • 13.1.28. WuXi AppTec
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing